INTRODUCTION
Estrogenic therapy of acromegalic patients has been shown to result in clinical benefit (1), decrease of elevated serum phosphorus levels and of urinary calcium excretion (2) , and amelioration of glucose intolerance (3, 4) . However, in four of five patients thus far reported, administration of estrogen did not reduce elevated plasma levels of radioimmunoassayable growth hormone (4, 5) . The present studies have attempted to define the effect of estrogen therapy upon four male acromegalic patients. None of the patients showed sigPreliminary reports of this work were published in abstract form: J. Clin. Invest. 46: 1115 and presented at the International Symposium on Growth Hormone, Milan, Italy, September 1967.
Received for publication 10 June 1968 and in revised form 20 September 1968. nificant decline of elevated basal plasma growth hormone levels, but all patients manifested a return towards normal of abnormal chemical and radiocalcium kinetic parameters.
METHODS
Clinical data and protocol. The subjects were four male acromegalic patients with elevated plasma growth hormone levels and normal thyroidal, adrenal, and gonadal function. Subject S.P., age 45, had the onset of acromegaly at age 24, and at age 36 of diabetes mellitus treated with NPH insulin,1 45-100 U daily. At age 36, he was given three separate courses of radiotherapy to the pituitary gland, with a dosage totaling 7000 R. Subject G.H., age 43, had the onset of acromegaly at age 40 and had received no therapy. Subject M.L., age 44, had the onset of acromegaly at age 20, and had two courses of radiotherapy to the pituitary at age 33 and at age 40 totaling 7000 R. He had a subtotal tryroidectomy for a colloid adenoma at the age of 36, and subtotal gastrectomy for bleeding duodenal ulcer at the age of 41. Subject A.R., age 47, had the onset of acromegaly at age 26, and, at the age of 44, a course of radiotherapy to the pituitary gland totaling 4000 R. He had a subtotal thyroidectomy for a colloid adenoma at the age of 37, and passed a left renal calculus at the age of 46.
Before and during estrogen therapy, the four patients underwent various combinations of complete or partial metabolic balance studies (all patients), serial plasma growth hormone radioimmunoassay determinations (all patients), radiocalcium kinetic studies (three patients), and insulin and glucose tolerance tests (two patients). Patients FIGURE 3 Metabolic data in patient M.L., a 44 yr old acromegalic male. Estinyl therapy lowered urinary calcium, urinary hydroxyproline, and serum phosphorus, while elevating urinary nitrogen, and transiently elevating blood urea nitrogen. Deladumone therapy produced similar effects upon urinary calcium, urinary hydroxyproline, and serum phosphorus, but a potent nitrogen-anabolic effect was observed which attributed to the testosterone-enanthate component of the drug. Elevated plasma growth hormone levels fluctuated independently of sex hormone administration.
unit (6, 7) . In patient S.P., urinary and fecal calciums were determined by a modified ultramicro ethylenediaminetetraacetate titration method, with cal-red as indicator (8) . In the other three patients, calcium determinations were performed by atomic absorption spectrophotometry, with the Perkin-Elmer model 303 instrument and a modification of the method of Willis (9) . Blood sugars were determined by Technicon automated analysis with ferricyanide reduction. In patients S.P. and G.H., conventional stool-marking techniques were used at 6-day intervals, with carmine red capsules and Taxation with bisacodyl or sennokot tablets. In patients M.L. and A.R., fecal marking was accomplished by
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blood urea nitrogen, and a sustained elevation, during estrogen therapy, of urinary nitrogen, resulting in more negative nitrogen balance. Fluctuations in the elevated plasma growth hormone level were not grossly affected by estrogen therapy. The black areas labeled Phleb refer to the nitrogen loss in blood withdrawn for tests. (10) . The nitrogen balance data were corrected for losses caused by phlebotomy for chemistries and radiocalcium studies (6) . Urinary hydroxyproline determinations were made by the method of Prockop and Udenfriend (11) . Plasma growth hormone and insulin levels were determined by the radioimmunoassay method (12, 13 (Fig. 6) , while patient A.R. had a much lower and probably nonsignificant response (Fig. 8) .
Throughout the studies, plasma growth hormone levels fluctuated by as much as +50% of the mean values. These fluctuations may have been physiological in origin and perhaps partly due to lack of assay precision at high growth hormone levels. In one patient, G.H., whose mean growth hormone levels were comparable before and after cessation of estrogen therapy (15.4 mpg/ml and 14.8 m/g/ml, respectively), the first of three assay values obtained during 9 days of estrogen therapy was considerably lower (6 mptg/ml), but was not considered significant. In patient A.R., whose basal plasma growth hormone levels manifested especially extreme fluctuations, Estinyl therapy had no apparent effect. The mean assay values before (102 m/g/ml), during (103 mpg/ml), and after estrogen therapy (105 mpg/ml) were almost identical. In patient M.L., after discontinuance of Estinyl, and reestablishment of a postcontrol base line, weekly injections of 2 ml of Deladumone were begun (1 ml = testosterone enanthate, 90 mg + estradiol valerate, 4 mg), to ascertain if the androgen in a sexually neutral preparation would modify the action of estrogen. Allowing for the random fluctuations observed in this patient, we judged that the androgenestrogen mixture also had no significant effect upon plasma growth hormone levels (Fig. 3) .
Glucose tolerance, insulin secretion, and insulin sensitivity (Figs. 5-8 returned to control levels after discontinuance of estrogen. Patient A.R. manifested moderately impaired glucose tolerance before, during, and after estrogen therapy, and his relatively normal insulin response remained essentially unchanged (Fig. 6) . The fasting plasma insulin concentrations in both patients appeared to be slightly elevated (40 ,U/ml in M.L.; 45 juU/ml in A.R.) and were not grossly altered by estrogen therapy.
(The normal value for fasting insulin concentration in our laboratory is approximately 20 ,uU/ml.) Insulin sensitivity with respect to glucose, with regular insulin in a dosage of 0.1 U/kg, was not significantly altered by estrogen therapy in patient M.L. (Fig. 7) and may have increased in patient A.R. (Fig. 8) approximate calcium intake, 1.0 glday 4~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ lated by us previously from composite normal data (7), the control accretion rates were elevated in the three patients studied (S.P., M.L., and A.R.). In each patient, the marked reductions of urinary calcium effected by estrogen therapy were associated with reductions of accretion rate, of exchangeable calcium pool, and of total radioisotope excretion. In two patients (S.P. and A.R.), intestinal calcium absorption was sharply reduced. The accretion rates declined from 0.85 g/day to 0.52 g/day (S.P.), from 1.41 g/day to 1.03 g/day (M.L.), and. from 1.69 g/day to 1.28 g/day (A.R.).
The rapidly exchangeable calcium (2 hr pool) values showed no consistent pattern of alteration. Hydroxyproline excretion (Table II, Figs. 1-4 ). In patients G.H., M.L., and A.R., average control 24-hr urinary hydroxyproline values of 102, 106, and 94 mg, respectively, were reduced by estrogen therapy to minimum levels of 73 mg/day, 57 mg/day, and 60 mg/day. In patient M.L., whose urinary hydroxyproline fell to 57 mg/day during the last 37 of 52 days of estrogen therapy, the discontinuance of estrogen was followed by a rise of hydroxyproline excretion to 92 mg/day averaged over a 27 day postcontrol period. The institution in patient M.L. of weekly intramuscular estrogen-androgen therapy as Deladumone was again followed by a reduction of urinary hydroxyproline to 55 mg/day, averaged over the last 18 days of an observation period of 36 days.
Serum phosphorus and the nitrogen balance (Table   II, Figs. 1-4) . In three of the four patients, (G.H., M.L., and A.R.), estrogen therapy reduced serum phosphorus concentration from levels of 5 mg/100 ml or higher to 4 (16) . Likewise, the elevation of urinary hydroxyproline excretion seen in acromegalic patients (17) , growing children (17) , and in normal adults given growth hormone (18) (19) . Overall, increased bone formation in acromegaly, as evidenced by elevated radiocalcium accretion rates in these studies and in others (20) , probably predominates over increased bone resorption, since the acromegalic skeleton is larger and heavier than normal. The reduction by estrogen of radiocalcium bone accretion rates in our patients may partially reflect a coupled response to a primary inhibition of elevated bone resorption (7) . However, it is probably also due to antagonism of the boneformation-stimulating property of growth hormone. Estrogen therapy reduces elevated plasma sulfation factor in acromegaly (21) , and partially inhibits growth hormone stimulation of epiphyseal growth in the hypophysectomized rat (22) . Androgens may share this property, as shown by the reduction of bioassayable epiphyseal-stimulating activity in the blood of a testosterone-treated acromegalic patient (23) .
The suppression by estrogen therapy of elevated serum phosphorus levels in acromegalic patients has been repeatedly observed in the past (1, 2, 21) . Serum phosphorus levels are high in growing children (24) and are readily elevated by administration of growth hormone to normal patients (18, 25) , an effect attributed to increased tubular reabsorption of phosphate (25) . Elevation by estrogen therapy of the blood urea nitrogen levels and negative effects -upon nitrogen balance in acromegaly have not been previously described. Estrogen was reported not to affect nitrogen balance in two acromegalic patients (26) , but the patients were in strongly positive nitrogen balance on respective intakes of 17.5 and 21 g of nitrogen per day. Our patients were consuming much lower nitrogen intakes of 13.5 and 14.5 g/day, respectively.
The variable patterns of glucose tolerance, insulin secretion, and insulin sensitivity observed in our patients, and by others in acromegaly, obscure the interpretation of estrogenic effects. As observed in patient M.L., estrogen therapy clearly ameliorated abnormal glucose tolerance in each of five female acromegalic patients described by McCullagh, Beck and Schaffenburg (3), and initially seemed to improve the glucose tolerance of the four patients described by Mintz, Finster, and Josimovich (4). In the latter study, three of the four patients initially manifested hyperinsulinemic responses to oral glucose, and all three patients had reduction of insulin response during estrogen therapy. In contrast, our two patients did not manifest high insulin responses to glucose in the control studies, but patient M.L. manifested a hyperinsulinemic response after estrogen therapy. Hyperinsulinemia after oral glucose occurs only in about 50% of acromegalic patients and is not related to the normality or abnormality of glucose tolerance tests (27, 28) . The finding of increased insulin response in patient M.L. after estrogen therapy resembles the augmentation of insulin response to intravenous glucose reported with estrogen-progestin contraceptive drug therapy (29) . The mechanism of this effect is unclear, but it is associated with deterioration of glucose tolerance, which was not seen in patient M.L. Only one of our two patients (A.R.) appeared somewhat more sensitive to insulin while on estrogen threapy, a finding described in acromegalic males treated with estrogen (2) , and in two of the four females treated by Mintz et al. (4) .
As observed in each of our four patients, in four of five acromegalic patients reported in the literature (4, 5) , estrogen therapy did not reduce elevated basal levels of radioimmunoassayable growth hormone. One patient (4) had an apparent decrease in plasma growth hormone from an initial level of approximately 50 mtxg/ ml to 15 m/Ag/ml after 1 month of estrogen therapy.
These values were apparently only single determinations and may not significantly differ from expected random fluctuations. The failure of estrogen therapy in patients M.L. and A.R. to reduce growth hormone levels in the basal state, after oral glucose, or after insulin-induced hypoglycemia, suggests that the alterations of urinary calcium and hydroxyproline excretion, serum phosphorus, blood urea nitrogen, nitrogen balance, and of radiocalcium kinetic parameters were not due to over-all reductions in growth hormone secretion, but rather to estrogenic effects at the periphery. This conclusion is consistent with the results of other metabolic studies in our unit ( [18] and to be reported) which demonstrate estrogenic antagonism of the effects of growth hormone administered to nonacromegalic patients.
